These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32578964)

  • 21. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
    Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
    Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
    Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA;
    J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
    Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
    Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
    Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
    Gainer JL; Sheehan JP; Larner JM; Jones DR
    J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.